biostudies-literatureTansley SLVersus ArthritisWellcome Trust2204-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC4241891biostudies-literatureUnknown53(12)<h4>Objective</h4>Calcinosis is a major cause of morbidity in JDM and has previously been linked to anti-NXP2 autoantibodies, younger age at disease onset and more persistent disease activity. This study aimed to investigate the clinical associations of anti-NXP2 autoantibodies in patients with JDM stratified by age at disease onset.<h4>Methods</h4>A total of 285 patients with samples and clinical data were recruited via the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-NXP2 was determined by both immunoprecipitation and ELISA. Logistic regression analysis was performed to assess the age-dependent relationship between anti-NXP2 and the development of calcinosis and disease activity measures.<h4>Results</h4>We identified anti-NXP2 autoantibodies in 56 patientsRheumatology (Oxford, England)Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.PMC42418911451808586018474Juvenile Dermatomyositis Research GroupArnold KShaddick GMcHugh NJWedderburn LRBetteridge ZETansley SLGunawardena HfalseCalcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.<h4>Objective</h4>Calcinosis is a major cause of morbidity in JDM and has previously been linked to anti-NXP2 autoantibodies, younger age at disease onset and more persistent disease activity. This study aimed to investigate the clinical associations of anti-NXP2 autoantibodies in patients with JDM stratified by age at disease onset.<h4>Methods</h4>A total of 285 patients with samples and clinical data were recruited via the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-NXP2 was determined by both immunoprecipitation and ELISA. Logistic regression analysis was performed to assess the age-dependent relationship between anti-NXP2 and the development of calcinosis and disease activity measures.<h4>Results</h4>We identified anti-NXP2 autoantibodies in 56 patients2014-01-01T00:00:00Z2014 Dec2026-05-07T03:06:03.013Z2026-04-07T22:33:42.704ZS-EPMC42418912498715810.1093/rheumatology/keu259